| 2.70 |  +0.04 / +1.50% |
Data as of May 23 | Day’s Change |
| 2.23 |  -0.47 / -17.41% |
Volume: 1.7K |
| 2013 FDA Drug Approval Calendar May 21 / TheStreet.com |
| Previous close | 2.66 |
| Today’s open | 2.68 |
| Day’s range | -- - -- |
| Volume | 2,487,368 |
| Average volume (3 months) | 1,984,539 |
| Market cap | $140.1M |
| Dividend yield | -- |
| Earnings growth (last year) | -456.76% |
| Earnings growth (this year) | +11.62% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -88.30% |
| P/E ratio | NM |
| Price/Sales | 18.10 |
| Price/Book | 0.99 |
| Today’s change | Today’s % change | |
|---|---|---|
| ALIMAlimera Sciences Inc | +0.01 | +0.23% |
| ENZNEnzon Pharmaceutical... | +0.09 | +2.93% |
| MEIPMEI Pharma Inc | -0.10 | -1.19% |
| KBIOKaloBios Pharmaceuti... | -0.04 | -0.70% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.57 |
| Annual revenue (last year) | $19.3M |
| Annual profit (last year) | -$114.4M |
| Net profit margin | -593.15% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Tuan Ha-Ngoc, MBA |
Chief Operating Officer & Executive Vice President Elan Z. Ezickson |
Corporate headquarters Cambridge, Massachusetts |
.
